A Phase Ib/IIa multicentric study to determine the safety and efficacy of a combination of anti-CD3 & anti-CD7 ricin A immunotoxins (T-Guard) for the treatment of steroid-resistant acute Graft-versus-Host Disease

Trial Profile

A Phase Ib/IIa multicentric study to determine the safety and efficacy of a combination of anti-CD3 & anti-CD7 ricin A immunotoxins (T-Guard) for the treatment of steroid-resistant acute Graft-versus-Host Disease

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Anti-CD3-ricin chain A conjugate/anti-CD7-ricin chain A conjugate (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Sponsors Xenikos
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Jan 2017 Status changed from recruiting to completed.
    • 10 Dec 2016 This trial has been completed in Germany (end date: 2016-11-03), according to European Clinical Trials database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top